T. Rowe Price Associates’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.27M | Buy |
182,941
+38,237
| +26% | +$513K | ﹤0.01% | 1774 |
|
|
2025
Q4 | $1.82M | Buy |
144,704
+7,015
| +5% | +$80.3K | ﹤0.01% | 1795 |
|
|
2025
Q3 | $1.38M | Buy |
137,689
+7,040
| +5% | +$63.2K | ﹤0.01% | 1910 |
|
|
2025
Q2 | $1.06M | Buy |
130,649
+3,973
| +3% | +$30K | ﹤0.01% | 1964 |
|
|
2025
Q1 | $1.06M | Buy |
126,676
+29,426
| +30% | +$246K | ﹤0.01% | 1929 |
|
|
2024
Q4 | $771K | Buy |
97,250
+9,704
| +11% | +$81.4K | ﹤0.01% | 2086 |
|
|
2024
Q3 | $729K | Buy |
87,546
+1,519
| +2% | +$11.9K | ﹤0.01% | 2097 |
|
|
2024
Q2 | $547K | Buy |
86,027
+4,763
| +6% | +$30.2K | ﹤0.01% | 2158 |
|
|
2024
Q1 | $493K | Buy |
81,264
+5,146
| +7% | +$29K | ﹤0.01% | 2217 |
|
|
2023
Q4 | $463K | Buy |
76,118
+1,949
| +3% | +$8.68K | ﹤0.01% | 2210 |
|
|
2023
Q3 | $313K | Buy |
74,169
+2,361
| +3% | +$8.8K | ﹤0.01% | 2314 |
|
|
2023
Q2 | $223K | Buy |
71,808
+51,989
| +262% | +$111K | ﹤0.01% | 2483 |
|
|
2023
Q1 | $28K | Buy |
19,819
+2,203
| +13% | +$4.39K | ﹤0.01% | 2835 |
|
|
2022
Q4 | $35K | Buy |
17,616
+525
| +3% | +$1.18K | ﹤0.01% | 2851 |
|
|
2022
Q3 | $35K | Buy |
+17,091
| New | +$47.9K | ﹤0.01% | 2873 |
|
|
2019
Q4 | – | Sell |
-11,283,585
| Closed | -$32.7M | – | 2528 |
|
|
2019
Q3 | $32.7M | Sell |
11,283,585
-7,382,540
| -40% | -$25.8M | ﹤0.01% | 1011 |
|
|
2019
Q2 | $134M | Sell |
18,666,125
-1,195,293
| -6% | -$12.2M | 0.02% | 570 |
|
|
2019
Q1 | $281M | Buy |
19,861,418
+239,722
| +1% | +$3.17M | 0.04% | 378 |
|
|
2018
Q4 | $265M | Buy |
19,621,696
+8,551,192
| +77% | +$154M | 0.04% | 361 |
|
|
2018
Q3 | $246M | Buy |
11,070,504
+11,027,092
| +25,401% | +$232M | 0.04% | 426 |
|
|
2018
Q2 | $712K | Buy |
+43,412
| New | +$762K | ﹤0.01% | 1992 |
|
Other funds holding AMRX
TGA
VPM
RCMNY
VCM
